Ionis Pharmaceuticals Inc
IONS69.150USD
+0.750+1.10%
Close 10/03, 16:00（ET）Quotes delayed by 15 min
11.01BMarket Cap
LossP/E TTM
More Details of Ionis Pharmaceuticals Inc Company
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Ionis Pharmaceuticals Inc Info
Ticker SymbolIONS
Company nameIonis Pharmaceuticals Inc
IPO dateMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Number of employees1069
Security typeOrdinary Share
Fiscal year-endMay 17
Address2855 Gazelle Court
CityCARLSBAD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92010
Phone17609319200
Websitehttps://www.ionis.com/
Ticker SymbolIONS
IPO dateMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Company Executives of Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.01K
--
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
79.66K
-11.15%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
57.13K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.83K
+0.29%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
37.42K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.01K
--
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
79.66K
-11.15%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
57.13K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.83K
+0.29%
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Other
51.29%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
Other
51.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
70.88%
Investment Advisor/Hedge Fund
17.08%
Hedge Fund
16.01%
Research Firm
2.02%
Pension Fund
1.13%
Individual Investor
0.78%
Bank and Trust
0.68%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
790
172.50M
108.22%
-7.29M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
23.64M
14.83%
+29.41K
+0.12%
Jun 30, 2025
The Vanguard Group, Inc.
16.68M
10.47%
+329.29K
+2.01%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.05M
10.07%
-126.81K
-0.78%
Jun 30, 2025
Capital World Investors
12.54M
7.87%
+178.19K
+1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
5.47%
-171.64K
-1.93%
Jun 30, 2025
Bellevue Asset Management AG
7.85M
4.93%
--
--
Jun 30, 2025
Wellington Management Company, LLP
6.35M
3.98%
-2.07M
-24.60%
Jun 30, 2025
Deep Track Capital LP
4.89M
3.07%
+327.34K
+7.17%
Jun 30, 2025
State Street Global Advisors (US)
4.53M
2.84%
-314.74K
-6.50%
Jun 30, 2025
Two Sigma Investments, LP
4.46M
2.8%
+678.11K
+17.95%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Russell 3000 ETF
0%
iShares Russell 1000 Value ETF
0%
Fidelity MSCI Health Care Index ETF
0%
VanEck Morningstar SMID Moat ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
JPMorgan BetaBuilders US Mid Cap Equity ETF
0%
iShares Russell 2500 ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0%
View more
iShares Russell 3000 ETF
Proportion0%
iShares Russell 1000 Value ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
VanEck Morningstar SMID Moat ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
JPMorgan BetaBuilders US Mid Cap Equity ETF
Proportion0%
iShares Russell 2500 ETF
Proportion0%
iShares US Small-Cap Equity Factor ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
